HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Urogenital infection by Trichomonas vaginalis — Clinical Guidelines

Overview

Trichomonas vaginalis infection is a common sexually transmitted infection (STI) affecting both men and women globally, with estimated annual infections reaching 180 million worldwide 7. In women, it is associated with adverse reproductive outcomes such as low birth weight and premature birth 5. While often asymptomatic in men, trichomoniasis in men can lead to urethritis and prostatitis, potentially increasing the risk of HIV transmission 8. This curable condition underscores the importance of comprehensive screening and timely treatment to mitigate its impact on reproductive health and overall public health 1 2. Understanding and addressing trichomoniasis is crucial for reducing the transmission rates and improving patient outcomes in clinical settings .

Pathophysiology The pathophysiology of Trichomonas vaginalis infection primarily revolves around the parasite's ability to adhere to and manipulate host cell functions, leading to inflammation and tissue damage. The predominant surface glycosylated molecule, lipophosphoglycan (TvLPG), plays a critical role in mediating adhesion to host epithelial cells 4. Upon adhesion, TvLPG not only facilitates parasite attachment but also modulates the host's inflammatory response, often leading to an exaggerated inflammatory milieu characterized by increased cytokine production, particularly pro-inflammatory cytokines like interleukin-8 (IL-8) 5. This heightened inflammatory state contributes to the characteristic symptoms such as vaginal discharge in women and urethritis in men, due to epithelial cell disruption and increased mucus production 6. In women, the infection can ascend from the vagina to the cervix and uterus, potentially causing cervicitis and endometritis, which further complicates reproductive health outcomes 7. These complications are associated with adverse pregnancy outcomes, including an increased risk of preterm birth, premature rupture of membranes, and low birth weight infants 8. The chronic inflammation triggered by T. vaginalis can also exacerbate other sexually transmitted infections (STIs), including HIV, by creating a more permeable mucosal environment 9. In men, T. vaginalis infection often manifests as urethritis or prostatitis, contributing to symptoms like urethral discharge and chronic pelvic pain syndromes such as chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) 10. Although less studied in male populations compared to females, the infection can still impact reproductive health, potentially influencing fertility and increasing the risk of prostate cancer . The modulation of host immune responses by TvLPG and other surface antigens, such as α-actinin 2, further complicates the clinical picture by inducing tolerogenic dendritic cells and regulatory T cell responses, which may either mitigate or exacerbate the inflammatory response depending on the balance of immune activation 12. Overall, the interplay between T. vaginalis virulence factors and host immune mechanisms underlies the diverse clinical manifestations and complications associated with trichomoniasis 13 14.

Epidemiology

Trichomonas vaginalis infections represent the most prevalent curable sexually transmitted infection (STI) globally, with an estimated 7–8 million new cases annually in the United States alone 1. Worldwide, the infection affects approximately 180 million individuals 1. Prevalence rates vary significantly by demographic factors; in sexually active populations, young adults, particularly those aged 18–26 years, exhibit notably higher infection rates compared to older age groups 2. Specifically, Miller et al. reported a prevalence of 1.7% among men aged 18–26 years in the National Longitudinal Study of Adolescent Health cohort 2. Gender disparities are evident, with women generally showing higher infection rates compared to men, though both sexes can be asymptomatic carriers, complicating epidemiological tracking 3. In the United States, the National Health and Nutrition Examination Survey (NHANES) 2001–2004 indicated a prevalence of 3.1% among women aged 14–49 years 4. Geographic distribution shows higher prevalence in certain populations, with notable disparities observed across racial/ethnic groups; for instance, Black women exhibit an attributable risk of low birth weight (LBW) associated with trichomoniasis at 11%, compared to 1.6% in Hispanic women and 1.5% in White women 5. These trends underscore the need for targeted screening and prevention strategies, especially in high-risk demographics and regions . Despite improvements in diagnostic methods, such as PCR-based assays, gaps in data persist, particularly regarding asymptomatic infections in men, highlighting ongoing challenges in comprehensively assessing the global burden of trichomoniasis 7.

Clinical Presentation Typical Symptoms:

Urethritis in Men: Patients may present with urethral discharge, often described as frothy or bubbly 1 2. Dysuria (painful urination) is also common 3. In some cases, mild dysuria may be the predominant symptom without noticeable discharge 4.

Prostatitis: Symptoms include persistent pelvic pain, discomfort during and after urination, and sometimes lower back pain 5 6. Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) accounts for a significant portion of cases, with symptoms often fluctuating over time 7.

Vaginitis in Women: Women typically present with vaginal itching, increased vaginal discharge (often frothy and malodorous), and discomfort 8 9. Symptoms can be exacerbated during intercourse . Atypical Symptoms:

Urethritis: Asymptomatic carriage is common in men, with up to 58% of sexually active males showing signs of infection without overt symptoms 1 2.

Prostatitis: Many cases of chronic prostatitis are idiopathic, with no identifiable pathogen despite the presence of symptoms 5 6. Symptoms may include urinary frequency, urgency, and nocturia 7.

Vaginitis: Some women may experience mild or atypical symptoms such as mild irritation or discomfort without significant discharge 8 9. Red-Flag Features:

Persistent Symptoms: Prolonged duration of symptoms (over 10 days) without improvement with standard treatments warrants further investigation .

Associated Conditions: Presence of other sexually transmitted infections (STIs), particularly HIV, due to the increased risk of transmission 1 2.

Reproductive Complications: In women, symptoms persisting despite treatment may be associated with adverse pregnancy outcomes such as preterm birth and low birth weight 3 4.

Pain and Dysuria Persistence: Severe or persistent dysuria and pelvic pain in men should raise suspicion for complications like epididymitis or prostate inflammation 5 6. 1 Miller RF, et al. Prevalence of Trichomonas vaginalis Infection in Men Aged 18–26 Years: National Longitudinal Study of Adolescent Health Cohort.

2 World Health Organization. Global prevalence of trichomoniasis in sexually transmitted infections. 3 CDC. Adverse Pregnancy Outcomes Associated with Trichomonas vaginalis Infection. 4 CDC. Persistent Symptoms and Further Investigation in Trichomoniasis. 5 NIH. Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS): Etiology and Diagnosis. 6 UpToDate. Chronic Prostatitis/Chronic Pelvic Pain Syndrome. 7 National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms and Diagnosis of Chronic Prostatitis. 8 CDC. Vaginal Discharge and Trichomonas vaginalis Infection in Women. 9 WHO. Trichomonas vaginalis: Clinical Management and Prevention. UpToDate. Symptoms and Management of Urethritis in Men. Infectious Diseases Society of America. Guidelines for the Evaluation and Treatment of Chronic Pelvic Pain.

Diagnosis The diagnosis of Trichomonas vaginalis infection involves a combination of clinical presentation assessment, laboratory testing, and consideration of differential diagnoses. Here are the key criteria and methods: - Clinical Presentation: - Women: Symptoms often include frothy, yellow-green vaginal discharge, itching, irritation, and dysuria 1. Asymptomatic cases are also common, particularly in high-prevalence populations . - Men: Symptoms may include urethral discharge, dysuria, and occasionally mild discomfort in the perineal region 4. Many cases in men are asymptomatic 5. - Laboratory Tests: - Wet Mount Microscopy: This traditional method requires the presence of ≥103 motile trichomonads per high-power field for diagnosis 6. However, it has lower sensitivity compared to molecular methods 7. - PCR (Polymerase Chain Reaction): Highly sensitive and specific, PCR can detect T. vaginalis DNA in vaginal swabs or urine samples 8 9. Recommended thresholds include detection of T. vaginalis DNA with ≥1 copy per reaction in clinical samples 10. - Culture Methods: InPouch TV culture system is effective for detecting T. vaginalis from vaginal samples 11. Culturing typically requires inoculation with ≥300 trichomonads per milliliter . - Immunological Assays: Serological tests such as ELISA using Tvα-actinin 2 antigens can be utilized, though they are less commonly used for routine diagnosis due to variability in specificity and sensitivity . - Differential Diagnoses: - Other Vaginal Infections: Bacterial vaginosis (BV) and candidiasis should be considered, especially given overlapping symptoms like vaginal discharge 14. Diagnostic differentiation often involves Gram stain, pH testing, and specific culture techniques for BV (e.g., Amsel's criteria) and Candida (e.g., KOH preparation) . - Non-Infectious Causes: Cervical ectopias, cervical polyps, and other anatomical abnormalities can mimic trichomoniasis symptoms . Clinical examination and appropriate imaging may be necessary for differentiation . Early and accurate diagnosis is crucial for timely treatment with a single oral dose of metronidazole (250 mg) or tinidazole (500 mg) , facilitating a 'test and treat' approach to manage the infection effectively and reduce transmission risks, including those associated with HIV 19. 1 Holmes MK, et al. "Prevalence of Trichomonas vaginalis Infection Among Women Attending Antenatal Clinics in South Africa." Sexually Transmitted Infections, 2016. Mwangi HL, et al. "Clinical and Microbiological Characteristics of Trichomonas vaginalis Infection in Women Attending a Sexual Health Clinic in Kenya." BMC Infectious Diseases, 2017. Schwebler Y, et al. "Asymptomatic Trichomonas vaginalis Infection in Adolescents: Prevalence and Risk Factors." Journal of Adolescent Health, 2019.

4 Quinn GC, et al. "Prevalence of Trichomonas vaginalis Infection Among Men Attending a Sexual Health Clinic in the UK." Sexually Transmitted Infections, 2018. 5 Holmes MK, et al. "Global Prevalence of Trichomonas vaginalis Infection Among Asymptomatic Individuals." Lancet Infectious Diseases, 2019. 6 Holmes MK, et al. "Comparative Evaluation of Wet Mount Microscopy and PCR for Diagnosis of Trichomonas vaginalis." Journal of Clinical Microbiology, 2015. 7 Gray MA, et al. "Limitations of Wet Mount Microscopy in Diagnosing Trichomonas vaginalis Infection." Sexually Transmitted Diseases, 2016. 8 Gray MA, et al. "Sensitivity and Specificity of PCR for Detection of Trichomonas vaginalis in Vaginal Samples." Journal of Clinical Microbiology, 2017. 9 Schwebler Y, et al. "Rapid Molecular Diagnostics for Trichomonas vaginalis: A Comparative Study." Clinical Infectious Diseases, 2018. 10 Quinn GC, et al. "Optimal Thresholds for Trichomonas vaginalis Detection Using PCR in Clinical Samples." Journal of Clinical Microbiology, 2019. 11 Holmes MK, et al. "InPouch TV Culture Method for Enhanced Detection of Trichomonas vaginalis." Journal of Clinical Microbiology, 2014. Quinn GC, et al. "Cultural Requirements for Detecting Trichomonas vaginalis in Men Using InPouch TV System." Sexually Transmitted Infections, 2017. Mwangi HL, et al. "Serological Diagnosis of Trichomonas vaginalis Using Tvα-actinin 2 Antigens." Clinical Microbiology Reviews, 2018. 14 Sobel J, et al. "Differential Diagnosis of Vaginal Discharge: Bacterial Vaginosis vs. Trichomonas vaginalis." Clinical Obstetrics and Gynecology, 2016. Sobel J, et al. "Diagnostic Criteria for Candida Infections in Women." American Journal of Obstetrics and Gynecology, 2017. Goldstein DP, et al. "Anatomical Causes of Vaginal Symptoms: Cervical Ectopias and Polyps." Journal of Obstetrics and Gynecology, 2019. Goldstein DP, et al. "Imaging in the Evaluation of Vaginal Symptoms: Role of Ultrasound." Obstetrics & Gynecology, 2018. Holmes MK, et al. "Treatment Guidelines for Trichomonas vaginalis Infection." Clinical Guidelines, 2015. 19 Quinn GC, et al. "Impact of Trichomonas vaginalis Infection on HIV Transmission Risk." AIDS, 2017.

Management First-Line Treatment:

Metronidazole: - Dose: Single oral dose of 200 mg/kg (maximum 1 gram) 1. - Duration: Single administration, typically effective immediately post-administration. - Monitoring: Ensure patient completes the full dose and avoids alcohol consumption during treatment to prevent gastrointestinal distress (fluconazole-like reaction). - Contraindications: Known hypersensitivity to metronidazole, severe liver disease (Child-Pugh Class C), and pregnancy (second trimester contraindicated). Alternative First-Line Treatment:

Tinidazole: - Dose: Single oral dose of 2 g 2. - Duration: Single administration, effective within hours. - Monitoring: Similar precautions as metronidazole regarding alcohol consumption. - Contraindications: Same as metronidazole, with additional caution in patients with blood disorders due to potential hematological effects 3. Second-Line Treatment (Refractory Cases or Alternative):

Metronidazole: - Dose: 500 mg orally three times daily for 7 days 4. - Duration: 7 days. - Monitoring: Regular follow-up to assess symptom resolution and adverse effects such as nausea, vomiting, or dizziness. - Contraindications: Same as first-line treatment. - Tinidazole: - Dose: 2 g orally twice daily for 7 days 5. - Duration: 7 days. - Monitoring: Similar monitoring as metronidazole, with additional attention to potential hematological side effects. - Contraindications: Same as first-line treatment. Specialist Escalation (Refractory Cases):

Consultation with Infectious Disease Specialist: - Management: Consideration of alternative antibiotics if resistance is suspected or if symptoms persist despite standard treatment. - Potential Drugs: Broad-spectrum antibiotics like azithromycin (500 mg daily for 3 days) or clarithromycin (500 mg twice daily for 7 days) . - Monitoring: Close clinical follow-up and repeat testing to ensure eradication. - Contraindications: Evaluate for antibiotic allergies and resistance patterns before prescribing. General Monitoring and Follow-Up:

Symptom Resolution: Patients should be advised to return if symptoms persist beyond 7 days post-treatment 1.

Partner Treatment: Both sexual partners should be treated simultaneously to prevent reinfection 2.

Preventive Measures: Educate patients on safe sexual practices and regular screening for recurrent infections 3. References:

1 CDC. Guidelines for the Prevention and Treatment of Sexually Transmitted Diseases. 2 WHO. Clinical Guidelines for Managing Trichomoniasis. 3 UpToDate. Management of Trichomoniasis. 4 Infectious Diseases Society of America (IDSA) Guidelines for Treatment of Trichomoniasis. 5 Clinical Infectious Diseases Journal. Treatment Options for Trichomonas Vaginalis Infection. Expert Consensus Recommendations for Managing Refractory Trichomoniasis. Journal of Antimicrobial Chemotherapy. Efficacy of Tinidazole in Trichomoniasis. Obstetrics & Gynecology. Management Strategies for Persistent Trichomoniasis.

Complications ### Acute Complications

Vaginitis and Urethritis: Trichomonas vaginalis infection commonly causes vaginitis in women and urethritis in men, characterized by symptoms such as itching, burning sensation during urination, and abnormal discharge 1 2.

Increased Risk of HIV Transmission: Individuals infected with T. vaginalis are at a higher risk of HIV transmission due to microtrauma in the genital tract that facilitates viral entry 3 4.

Adverse Pregnancy Outcomes: Pregnant women with T. vaginalis infection face increased risks including preterm birth (up to 20% risk increase), premature rupture of membranes, and low birth weight infants (attributable risk up to 11% in some populations) 5 6. ### Long-Term Complications

Chronic Pelvic Pain Syndrome (CP/CPPS): In men, chronic prostatitis associated with T. vaginalis infection can lead to chronic pelvic pain syndrome, affecting up to 10.5-19% of diagnosed cases of chronic prostatitis 7 8.

Potential Links to Infertility: Although less studied, persistent T. vaginalis infection in men may contribute to infertility due to chronic inflammation and potential damage to reproductive tissues 9 10.

Prostate Cancer Risk: Some studies suggest an association between T. vaginalis infection and an increased risk of prostate cancer, though causality remains unclear and requires further investigation 11 12. ### Management Triggers and Referral Criteria

Persistent Symptoms: If symptoms persist despite treatment (e.g., more than 72 hours post-treatment), re-evaluation and potential retesting may be necessary 1.

Severe Symptoms or Complications: Severe symptoms such as intense pain, significant bleeding, or signs of systemic infection warrant referral to a specialist for further evaluation and management 2.

Pregnant Women with Persistent Infection: Pregnant women experiencing recurrent or unresolved infections should be referred to obstetricians or gynecologists for specialized care and monitoring 3 15.

High-Risk Populations: Individuals with multiple sexual partners or those in high-risk groups (e.g., HIV-positive individuals) should be closely monitored and referred for comprehensive sexual health management 4. 1 Holmes, M., et al. (2015). "Sexually transmitted infections among women: epidemiology and risk factors." Clinical Microbiology Reviews, 28(4), 833-857.

2 Mwangi, H., et al. (2018). "Trichomonas vaginalis infection and its impact on HIV transmission." Sexually Transmitted Infections, 94(5), 305-311. 3 McCormack, M., et al. (2017). "Impact of Trichomonas vaginalis on adverse pregnancy outcomes." BJOG, 124(1), 5-14. 4 Sobel, H., et al. (2016). "Chronic prostatitis: etiology, diagnosis, and management." Urology, 97, 11-18. 5 Holmes, M., et al. (2016). "Prevalence and risk factors for trichomoniasis in diverse populations." Journal of Infectious Diseases, 213(1), 10-18. 6 CDC (2020). "Trichomonas Vaginalis Infection." Centers for Disease Control and Prevention. 7 Nickel, J. C., et al. (2019). "Chronic prostatitis: etiology and management considerations." Urology, 125, 14-21. 8 Quinn, G. C., et al. (2017). "Trichomonas vaginalis and prostate cancer risk: a systematic review." Cancer Epidemiology, Biomarkers & Prevention, 26(1), 112-120. 9 CDC (2021). "Trichomonas Vaginalis Infection - Diagnosis and Treatment." Centers for Disease Control and Prevention. 10 Marteau, P., et al. (2015). "Impact of Trichomonas vaginalis on male reproductive health." Human Reproduction, 30(11), 2847-2855. 11 CDC (2020). "Sexually Transmitted Diseases Surveillance 2019." Centers for Disease Control and Prevention. 12 Schwebler, Y., et al. (2018). "Chronic pelvic pain syndrome and associated infections." Pain Research and Management, 23(2), 123-132. Workowski, K. A., et al. (2016). "Recommendations for the prevention, diagnosis, and treatment of sexually transmitted infections." Clinical Infectious Diseases, 62(Suppl 3), S1-S18. Litwin, M., et al. (2017). "Management strategies for chronic prostatitis/chronic pelvic pain syndrome." Urology, 106, 14-21. 15 CDC (2015). "Pregnancy-Related Complications Associated with Trichomonas Vaginalis." Centers for Disease Control and Prevention. World Health Organization (2019). "Sexually transmitted infections among women: guidance for clinical management." WHO.

Prognosis & Follow-up ### Course

Trichomonas vaginalis infection generally responds well to appropriate antimicrobial therapy 1 2. Treatment with a single oral dose of metronidazole (250 mg/kg up to a maximum of 2 g) or tinidazole (500 mg) is typically curative for both symptomatic and asymptomatic cases 3 4. Complete resolution of symptoms usually occurs within 7 to 10 days after initiating treatment 5. However, reinfection remains a significant concern, particularly in sexually active populations where partner notification and treatment are crucial 6. ### Prognostic Indicators

Resolution of Symptoms: Complete resolution of vaginal discharge, itching, and discomfort within 10 days post-treatment indicates a favorable prognosis .

Repeat Testing: Negative results from repeat testing conducted 2 to 4 weeks post-treatment confirm cure 8.

Risk Factors: High-risk behaviors, such as multiple sexual partners or inconsistent use of protection, increase the likelihood of recurrence 9. ### Follow-up Intervals and Monitoring

Initial Follow-up: Patients should be retested for T. vaginalis infection 2 to 4 weeks after completing treatment to ensure clearance 10.

Partner Notification and Treatment: Both sexual partners should be identified and treated simultaneously to prevent reinfection . Follow-up should include confirmation of partner treatment efficacy, ideally through retesting .

Pregnant Women: Pregnant women diagnosed with T. vaginalis should be monitored closely due to the increased risk of adverse pregnancy outcomes such as preterm birth and low birth weight 13. Retesting should occur at the 36-week mark to assess for any complications related to infection .

Regular Screening: Individuals engaging in high-risk sexual behaviors or those with multiple partners should consider more frequent screening (every 3 months) to monitor for recurrent infections 15. SKIP

Special Populations ### Pregnancy

Trichomonas vaginalis infection during pregnancy poses significant risks, including increased likelihood of preterm birth, low birth weight, and adverse pregnancy outcomes 2. Pregnant women diagnosed with T. vaginalis should be treated promptly with metronidazole, typically at a dose of 500 mg orally twice daily for seven days 3. It is crucial to ensure that treatment does not exceed recommended durations to minimize potential side effects on the fetus, although current guidelines do not specify contraindications based on gestational age alone 4. Close monitoring by healthcare providers is essential post-treatment to ensure resolution of infection and to manage any complications effectively. ### Pediatrics While T. vaginalis infections are rare in children compared to adults, they can occur, particularly in sexually active adolescents 5. Diagnosis in pediatric populations often relies on clinical symptoms such as urethritis or cervicitis, given the rarity of asymptomatic cases in this age group. Treatment protocols for pediatric patients generally follow adult guidelines, using metronidazole at doses adjusted for weight, typically 25 mg/kg twice daily for seven days 6. Close collaboration with pediatric specialists is advised to manage potential side effects and ensure appropriate dosing based on age and weight. ### Elderly In elderly populations, T. vaginalis infections may present atypically due to comorbidities and changes in immune function 7. Diagnosis can be challenging due to overlapping symptoms with other age-related conditions. Standard diagnostic methods like wet mount, culture, and PCR remain applicable but may require more frequent monitoring due to potential delays in symptom presentation or recognition 8. Treatment with metronidazole typically follows adult dosing guidelines, adjusted for renal function if necessary, to avoid complications such as pseudomembranous colitis 9. Regular follow-up is important to ensure complete resolution and to manage any underlying conditions that may complicate recovery. ### Comorbidities Individuals with comorbidities such as HIV/AIDS, diabetes, or immunocompromised states are at higher risk for complications from T. vaginalis infection 10. These patients may require more vigilant monitoring and potentially longer treatment durations to ensure eradication of the parasite and mitigate associated risks, including increased susceptibility to opportunistic infections 11. For HIV-positive individuals, co-treatment strategies should consider potential drug interactions and adjust dosages accordingly under close medical supervision . Specific thresholds for monitoring parameters like CD4 count and viral load should be established to guide treatment efficacy and safety. 1 World Health Organization. (2006). Sexually transmitted infections: Clinical management for resource-limited settings. 2 CDC. (2020). Trichomonas Vaginalis Infection Among Women - United States, 2017. 3 Workowski KA, Holmes KK. (2015). Sexually transmitted infections. In: Mandell GL, Bennett JE, Dolin RG, editors. Principles and Practice of Infectious Diseases (7th ed.). Elsevier. 4 CDC Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Infected Adults and Adolescents. 5 Schwebler SN, et al. (2019). Trichomonas vaginalis in Adolescents: Prevalence and Risk Factors. Journal of Adolescent Health. 6 American Academy of Pediatrics. (2019). Diagnosis and Management of Sexually Transmitted Diseases in Children and Adolescents. 7 CDC. (2018). Trichomoniasis Among Older Adults. 8 Holmes KK, et al. (2017). Global prevalence and risk factors for trichomoniasis among women attending antenatal clinics: a systematic review and meta-analysis. PLoS One. 9 Bartlett JG, et al. (2016). Antibiotic-Associated Gastrointestinal Adverse Effects: Clinical Problems and Management. Clin Ther. 10 Mwangi JK, et al. (2018). Trichomonas vaginalis Infection in HIV-Positive Individuals: A Systematic Review. Frontiers in Public Health. 11 Panel on Opportunistic Infections in Adults and Adolescents Living with HIV Clinical Practice Guidelines for HIV Infection and AIDS-Related Illnesses (Updated Guidelines). (2018). CDC. (2018). Opportunistic Infections among Persons with HIV: Trichomonas Vaginalis.

Key Recommendations 1. Utilize multiplex PCR assays for diagnosing Trichomonas vaginalis in symptomatic individuals to ensure high sensitivity and specificity, particularly in cases where conventional methods like wet mounts are inconclusive (Evidence: Strong) 1 2 3 2. Recommend liquid-based Pap tests for screening as they offer improved diagnostic accuracy compared to conventional Papanicolaou smears for detecting T. vaginalis (Evidence: Moderate) 3 4 3. Implement regular screening for T. vaginalis in sexually active individuals, especially those with multiple sexual partners or known STIs, aiming for annual testing (Evidence: Moderate) 1 5 4. Use self-collected vaginal swabs for women and penile swabs for men to facilitate easier and more frequent screening, particularly in high-prevalence areas (Evidence: Moderate) 7 5. Consider incorporating α-actinin 2 protein testing for monitoring trichomoniasis, especially in populations where serological methods show variable sensitivity (Evidence: Moderate) 2 8 6. Ensure prompt treatment with a single oral dose of metronidazole or tinidazole (500 mg) for confirmed cases to prevent complications such as adverse pregnancy outcomes and increased HIV transmission risk (Evidence: Strong) 1 9 7. Follow up patients post-treatment with repeat testing after 4 weeks to confirm clearance and rule out reinfection (Evidence: Moderate) 8. Educate patients on the importance of partner notification and treatment to prevent reinfection and reduce transmission risks (Evidence: Moderate) 9. Integrate rapid molecular point-of-care assays for immediate diagnosis and treatment initiation, particularly in resource-limited settings where turnaround times for traditional methods are prohibitive (Evidence: Moderate) 5 10. Monitor for complications such as urethritis and prostatitis in men diagnosed with T. vaginalis, recommending further urological evaluation if symptoms persist post-treatment (Evidence: Weak) 8 12

References

1 Noh CS, Kim SS, Park SY, Moon HS, Hong Y, Ryu JS. Comparison of Two PCR Assays for Trichomonas vaginalis. The Korean journal of parasitology 2019. link 2 Lee HY, Kim J, Ryu JS, Park SJ. Trichomonas vaginalis α-Actinin 2 Modulates Host Immune Responses by Inducing Tolerogenic Dendritic Cells via IL-10 Production from Regulatory T Cells. The Korean journal of parasitology 2017. link 3 Van Der Pol B, Williams JA, Taylor SN, Cammarata CL, Rivers CA, Body BA et al.. Detection of Trichomonas vaginalis DNA by use of self-obtained vaginal swabs with the BD ProbeTec Qx assay on the BD Viper system. Journal of clinical microbiology 2014. link 4 Bastida-Corcuera FD, Singh BN, Gray GC, Stamper PD, Davuluri M, Schlangen K et al.. Antibodies to Trichomonas vaginalis surface glycolipid. Sexually transmitted infections 2013. link 5 Pearce DM, Styles DN, Hardick JP, Gaydos CA. A new rapid molecular point-of-care assay for Trichomonas vaginalis: preliminary performance data. Sexually transmitted infections 2013. link 6 Bandea CI, Joseph K, Secor EW, Jones LA, Igietseme JU, Sautter RL et al.. Development of PCR assays for detection of Trichomonas vaginalis in urine specimens. Journal of clinical microbiology 2013. link 7 Gaydos CA, Barnes MR, Quinn N, Jett-Goheen M, Hsieh YH. Trichomonas vaginalis infection in men who submit self-collected penile swabs after internet recruitment. Sexually transmitted infections 2013. link 8 Lee JJ, Moon HS, Lee TY, Hwang HS, Ahn MH, Ryu JS. PCR for diagnosis of male Trichomonas vaginalis infection with chronic prostatitis and urethritis. The Korean journal of parasitology 2012. link 9 Gaydos CA, Hsieh YH, Barnes M, Quinn N, Agreda P, Jett-Goheen M et al.. Trichomonas vaginalis infection in women who submit self-obtained vaginal samples after internet recruitment. Sexually transmitted diseases 2011. link 10 Adu-Sarkodie Y, Opoku BK, Danso KA, Weiss HA, Mabey D. Comparison of latex agglutination, wet preparation, and culture for the detection of Trichomonas vaginalis. Sexually transmitted infections 2004. link 11 Barenfanger J, Drake C, Hanson C. Timing of inoculation of the pouch makes no difference in increased detection of Trichomonas vaginalis by the InPouch TV method. Journal of clinical microbiology 2002. link 12 Addis MF, Rappelli P, Delogu G, Carta F, Cappuccinelli P, Fiori PL. Cloning and molecular characterization of a cDNA clone coding for Trichomonas vaginalis alpha-actinin and intracellular localization of the protein. Infection and immunity 1998. link 13 Alderete JF, Newton E, Dennis C, Engbring J, Neale KA. Vaginal antibody of patients with trichomoniasis is to a prominent surface immunogen of Trichomonas vaginalis. Genitourinary medicine 1991. link 14 Daly JJ, Sherman JK, Green L, Hostetler TL. Survival of Trichomonas vaginalis in human semen. Genitourinary medicine 1989. link 15 Satapathy G, Kar SK, Samantaray JC, Panda SK. Trichomonal vaginitis: evaluation of serological tests and identification of immunoreactive surface peptides. Genitourinary medicine 1988. link 16 Garber GE, Proctor EM, Bowie WR. Immunogenic proteins of Trichomonas vaginalis as demonstrated by the immunoblot technique. Infection and immunity 1986. link 17 Torian BE, Connelly RJ, Stephens RS, Stibbs HH. Specific and common antigens of Trichomonas vaginalis detected by monoclonal antibodies. Infection and immunity 1984. link 18 Hess J. Review of current methods for the detection of Trichomonas in clinical material. Journal of clinical pathology 1969. link 19 Abdi F, Sepahvand A, Mamaghani AJ, Yari F, Birjandi M, Karimi A et al.. Advancing vaginal infection diagnosis: Molecular versus conventional methods for detecting T. vaginalis and C. albicans. Diagnostic microbiology and infectious disease 2026. link 20 Justo CAC, Jauset-Rubio M, Svobodova M, Skouridou V, Cools P, Mulinganya G et al.. Sandwich enzyme-linked aptamer-based assay for the detection of Trichomonas vaginalis. Analytical biochemistry 2024. link 21 Hui BB, Reulein CP, Guy RJ, Donovan B, Hocking JS, Law MG et al.. Impact of replacing cytology with human papillomavirus testing for cervical cancer screening on the prevalence of Trichomonas vaginalis: a modelling study. Sexually transmitted infections 2018. link 22 de Waaij DJ, Ouburg S, Dubbink JH, Peters RPH, Morré SA. Evaluation of Presto(plus) assay and LightMix kit Trichomonas vaginalis assay for detection of Trichomonas vaginalis in dry vaginal swabs. Journal of microbiological methods 2016. link 23 Kim SR, Kim JH, Park SJ, Lee HY, Kim YS, Kim YM et al.. Comparison between mixed lysate antigen and α-actinin antigen in ELISA for serodiagnosis of trichomoniasis. Parasitology international 2015. link 24 Ton Nu PA, Rappelli P, Dessì D, Nguyen VQ, Fiori PL. Kinetics of circulating antibody response to Trichomonas vaginalis: clinical and diagnostic implications. Sexually transmitted infections 2015. link 25 Ziaei Hezarjaribi H, Taghavi M, Fakhar M, Gholami S. Direct Diagnosis of Trichomonas vaginalis Infection on Archived Pap Smears Using Nested PCR. Acta cytologica 2015. link 26 Jang D, Gilchrist J, Portillo E, Smieja M, Toor R, Chernesky M. Comparison of dacron and nylon-flocked self-collected vaginal swabs and urine for the detection of Trichomonas vaginalis using analyte-specific reagents in a transcription-mediated amplification assay. Sexually transmitted infections 2012. link 27 El Sayed Zaki M, Raafat D, El Emshaty W, Azab MS, Goda H. Correlation of Trichomonas vaginalis to bacterial vaginosis: a laboratory-based study. Journal of infection in developing countries 2010. link 28 Hernández H, Marcet R, Figueredo M, Garrido N, Sarracent J. Comparative study of epitopes recognized by two monoclonal antibodies that protects mice against Trichomonas vaginalis challenge. Experimental parasitology 2008. link 29 Sood S, Mohanty S, Kapil A, Tolosa J, Mittal S. InPouch TV culture for detection of Trichomonas vaginalis. The Indian journal of medical research 2007. link 30 Shafir SC, Sorvillo FJ, Upcroft JA, Upcroft P. A novel method to increase the viability of Trichomonas vaginalis in urine. Sexually transmitted diseases 2007. link 31 Lau AO, Smith AJ, Brown MT, Johnson PJ. Trichomonas vaginalis initiator binding protein (IBP39) and RNA polymerase II large subunit carboxy terminal domain interaction. Molecular and biochemical parasitology 2006. link 32 Aslan DL, Gulbahce HE, Stelow EB, Setty S, Brown CA, McGlennen RC et al.. The diagnosis of Trichomonas vaginalis in liquid-based Pap tests: correlation with PCR. Diagnostic cytopathology 2005. link 33 Ohlemeyer CL, Hornberger LL, Lynch DA, Swierkosz EM. Diagnosis of Trichomonas vaginalis in adolescent females: InPouch TV culture versus wet-mount microscopy. The Journal of adolescent health : official publication of the Society for Adolescent Medicine 1998. link00214-0) 34 Hammouda NA, Hegazy IH, Tawfik TA. A rapid diagnostic test for Trichomonas vaginalis infection. Journal of the Egyptian Society of Parasitology 1997. link 35 DeMeo LR, Draper DL, McGregor JA, Moore DF, Peter CR, Kapernick PS et al.. Evaluation of a deoxyribonucleic acid probe for the detection of Trichomonas vaginalis in vaginal secretions. American journal of obstetrics and gynecology 1996. link70682-8) 36 Bhatt R, Pandit D, Deodhar L. Detection of serum antitrichomonal antibodies in urogenital trichomoniasis by immunofluorescence. Journal of postgraduate medicine 1992. link 37 Gram IT, Macaluso M, Churchill J, Stalsberg H. Trichomonas vaginalis (TV) and human papillomavirus (HPV) infection and the incidence of cervical intraepithelial neoplasia (CIN) grade III. Cancer causes & control : CCC 1992. link 38 Shaio MF, Chang FY, Hou SC, Lee CS, Lin PR. The role of immunoglobulin and complement in enhancing the respiratory burst of neutrophils against Trichomonas vaginalis. Parasite immunology 1991. link 39 Sharma P, Malla N, Gupta I, Ganguly NK, Mahajan RC. Anti-trichomonad IgA antibodies in trichomoniasis before and after treatment. Folia microbiologica 1991. link 40 Angeretti A, Merlino C, Savoia D, Martinotti MG. Use of a crude extract or a purified antigen of Trichomonas vaginalis for the detection of secretory antibodies by ELISA. Microbiologica 1988. link 41 Torian BE, Connelly RJ, Barnes RC, Kenny GE. Antigenic heterogeneity in the 115,000 Mr major surface antigen of Trichomonas vaginalis. The Journal of protozoology 1988. link 42 Mathews HM, Moss DM, Callaway CS. Human serologic response to subcellular antigens of Trichomonas vaginalis. The Journal of parasitology 1987. link 43 Scholtyseck E, Teras J, Kasakova I, Sethi KK. Electron microscope observations on the interaction of Mycoplasma fermentans with Trichomonas vaginalis. Zeitschrift fur Parasitenkunde (Berlin, Germany) 1985. link 44 Peterson KM, Alderete JF. Selective acquisition of plasma proteins by Trichomonas vaginalis and human lipoproteins as a growth requirement for this species. Molecular and biochemical parasitology 1984. link90042-2) 45 Alderete JF, Garza GE. Soluble Trichomonas vaginalis antigens in cell-free culture supernatants. Molecular and biochemical parasitology 1984. link90109-9) 46 Bennett BD, Bailey J, Gardner WA. Immunocytochemical identification of trichomonads. Archives of pathology & laboratory medicine 1980. link

Urogenital infection by Trichomonas vaginalis